Abstract 2134P
Background
Hodgkin’s lymphoma survivors (HLSs) are at risk for late effects due to their early age at diagnosis, multimodal therapy and long life expectancy. Among HLSs, we explored self-reported late effects, and assessed their information needs regarding lifestyle (diet and physical activity) and rehabilitation, in addition to need for long-term follow-up and factors associated with these needs.
Methods
HLSs treated 1997-2006 and aged 18-49 years at diagnosis were identified by the Norwegian Cancer Registry and invited to participate in this population-based, cross-sectional study consisting of a questionnaire, blood tests, clinical examination and echocardiography. Information regarding histology, stage and treatment was retrieved from medical records. Descriptive statistics and logistic regression models were used.
Results
Among the participants (n=304, 59% response rate), median age at diagnosis was 29 years (range 8-49), median age at survey 45 years (21-70), median observation time 16 years (10-22) and 48 % were females. Ninety percent had classical HL, 62% had stage I-IIA disease, 94% received chemotherapy and 77% radiotherapy. Seventy-four percent reported to have experienced ≥1 late effects; concentration/memory problems (29%), numbness/nerve pain (32%) and dental problems (27%) were the most common. Forty-one percent reported chronic fatigue (CF). One third reported to have received follow-up for late effects. A total of 64% wanted information about lifestyle and/or rehabilitation, and 58% wanted regularly follow-up for late effects. In the multivariable models, CF (OR 2.2, 95%CI 1.2-4.1), short education (2.2, 1.2-4.0), being physical inactive (2.0, 1.1-3.5) were associated with increased likelihood of need for information about lifestyle and/or rehabilitation. CF was associated with increased likelihood of need for follow-up for late effects (2.1, 1.3-3.6).
Conclusions
HLSs report a high level of late effects and only a small proportion receive follow-up for these problems. Chronic fatigue is associated with need for information and follow-up, indicating that these patients could benefit from a more structured model for long-term follow-up than what is currently available.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
Norwegian Cancer Society and the DAM foundation, project number 2019/FO247426; Norwegian Extra Foundation for Health and Rehabilitation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07